Cornea - ARVO

More documents

Recommendations

Info

ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - CorneaCommercial Relationships: Yutaka Sakurai, None; Masataka Ito,None; Yoko Karasawa, None; Yoshihiko Usui, None; TakaakiHattori, None; Hiroshi Goto, None; Masaru Takeuchi, NoneProgram Number: 919 Poster Board Number: B0224Presentation Time: 1:00 PM - 2:45 PMPotential Regulatory T Cell Mechanisms Of ImmuneSuppression In A Mouse Model Of Dry EyeKatherine S. Held 1 , Chris S. Schaumburg 1 , Jianping Gao 1 , Larry A.Wheeler 1 , Margarita Calonge 2 , Jerry Y. Niederkorn 4 , Stephen C.Pflugfelder 3 , Michael E. Stern 1 . 1 R&D, Allergan, Inc, Irvine, CA;2 IOBA, University of Valladolid, Valladolid, Spain; 3 Baylor Collegeof Medicine, Houston, TX; 4 Ophthalmology, UT SW-Med Center,Dallas, TX.Purpose: To evaluate immunosuppressive properties of inducibleand natural T regulatory (Tregs) subsets following induction ofexperimental dry eye in mice.Methods: Flow cytometry was utilized to characterize Tregs withinthe periphery during experimental dry eye to determine i) thefrequencies of inducible, iTregs, and natural, nTregs, and ii) the levelof expression markers indicating activation and the capacity forsuppression by metabolic disruption and dendritic cell immunemodulation. C57BL/6 wild-type female mice were exposed todesiccating environmental stress (DS; subcutaneous scopolamineinjections, humidity
ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Corneaaccording to two schedules: Schedule 1 (S1): to model prevention,dosing started at the beginning of housing in ICES (Day1) and lastedfor 21 days; Schedule 2 (S2): to model treatment, dosing started onDay22 after the housed mice developed dry eye and lasted untilDay35. The efficacy of the L-carnitine treatment compared to that ofthe vehicle (PBS) was tested for ocular surface integrity byfluorescein staining; corneal epithelial apoptosis by TUNEL orCaspase-3 assays; goblet cell numbers by PAS staining; andexpression of inflammatory mediators, TNF-α, IL-17, IL-6 or IL-1βusing real-time PCR, on Days 0, 14, 21 and/or 35.Results: Compared to the vehicle, eyes treated with L-carnitineshowed a significant reduction in corneal fluorescein staining on Day14, 21 and 35 for S1 (p=0.0001, 0.0001, and 0.017, respectively) andDay35 for S2 (p=0.0001); the number of TUNEL-positive apoptoticcorneal epithelial cells on Day21 for S1 (p=0.032) or Day35 for S2(p=0.005); the expression level of TNF-α, IL-17, IL-6, or IL-1β (allp0.05) among populations.In order to study the relation between genotype and phenotype, weperformed both additive and dominant gene model then did linearregression analysis, results of which indicated that EDAR V370Awas not correlated with MG density and diameter(p>0.05,Spearman).Conclusions: Genotyping revealed that difference of derived EDARallele frequency did exist among populations. Based on limited©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the ARVO Office at arvo@arvo.org.
Page 2 and 3: ARVO 2013 Annual Meeting Abstracts
Page 10: ARVO 2013 Annual Meeting Abstracts
Page 92 and 93:
ARVO 2013 Annual Meeting Abstracts
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
show all

Cornea - ARVO

Create successful ePaper yourself

Delete template?

Save as template?